Johnson & Johnson

Jefferies lowers Genmab's price target, focusing on Q1 2025 when J&J may decide on Darzalex successor.

GSK’s Blenrep, withdrawn in 2022, seeks FDA approval in combination with Velcade/dexamethasone or Pomalyst/dexamethasone for multiple myeloma patients with prior therapy. Based on DREAMM-7 and DREAMM-8 trials, Blenrep combos showed significant PFS improvements over standard-of-care, with manageable safety profiles. Expected to compete with BCMA CAR-T therapies like Carvykti and Tecvayli, Blenrep could offer simpler IV infusion benefits.

J&J and Protagonist Therapeutics report positive phase 3 results for icotrokinra in treating moderate-to-severe plaque psoriasis, with significant improvements in IGA and PASI scores compared to placebo.

Celltrion's Remsima, the world's first biosimilar monoclonal antibody, is expected to exceed 1 trillion won in sales in 2024, becoming the first Korean drug to hit this milestone. Remsima, approved by Europe in 2013 and the FDA in 2016, is available in over 100 countries and is cheaper than the original drug with the same efficacy, used for treating chronic diseases like rheumatoid arthritis.

The global biopharmaceuticals market is projected to reach USD 566 billion by 2032, driven by innovations in treating previously untreatable diseases. North America led in 2022 with a 43% share. Key players like Pfizer and InflaRx are advancing therapies, but challenges include high costs and regulatory complexities. The industry is also focusing on sustainability and digital transformation.

ChapsVision acquires Sinequa; Answer ALS and Cedars-Sinai release largest ALS iPSC and bio data repository; Healx to use Sanofi compound with AI platform Healnet; Scale Biosciences and BioLegend launch TotalSeq Phenocyte single-cell protein profiling solution; GeneDx introduces GeneDx Discover data visualization tool; Model N integrates generative AI and data capabilities; NCSA launches DeltaAI; Sapio Sciences and Waters Corporation enhance lab productivity; CapeStart debuts MadeAi platform; Trogenix unveils cancer treatment platform; Exagen submits new SLE and RA biomarkers for approval; C-Path launches GEM-PD initiative; BioNTech acquires Biotheus; Stand Up To Cancer collaborates with Johnson & Johnson on AL amyloidosis treatment; Nxera and Antiverse partner for GPCR antibody design; CCRM Nordic, Sahlgrenska Academy, and Sahlgrenska University Hospital form ATMP partnership; BC Platforms, Modirum Platforms, and VEIL.AI deploy software for EHDS2 framework; Evogene collaborates with Google Cloud on generative AI for small molecule design; Parse Biosciences launches GigaLab for single cell sequencing; Gingko Bioworks introduces Antibody Developability product.

GeneDx announced GeneDx Discover, a data visualization tool for biopharmaceutical companies to access deidentified genetic data. Critical Path Institute launched Gender Equitable Medicines for Parkinson's Disease (GEM-PD) to advance research on Parkinson's impact on women and across the sex and gender spectrum. CapeStart debuted MadeAi, a generative AI platform for clinical information synthesis. Capitainer expanded operations in the U.S. to enhance customer service. Stand Up To Cancer partnered with Johnson & Johnson to test a combination therapy for AL amyloidosis. Medable introduced Medable AI for faster digital and decentralized trial setup. CCRM Nordic, Sahlgrenska Academy, and Sahlgrenska University Hospital formed a strategic partnership for advanced therapy medicinal products (ATMPs).

Johnson & Johnson submitted an sBLA to the FDA for a subcutaneous induction regimen of Tremfya for UC, supported by the phase 3 ASTRO study. ASTRO met primary and secondary endpoints, showing clinical remission and endoscopic improvement. Tremfya, a dual-acting monoclonal antibody blocking IL-23 and binding to CD64, aims to offer a fully SC induction and maintenance regimen for IBD.

The article content is not provided for summarization.

Novartis acquires Kate Therapeutics for $1.1B, Barclays predicts challenging 2025 for European pharma, Trump picks surgeon Martin Makary to lead FDA, Novartis partners with Ratio Therapeutics for up to $745M, Kyowa Kirin pays Kura Oncology $330M upfront for leukemia drug rights, global measles cases rise 20% to 10.3 million, Brookfield considers €7B bid for Grifols, Bavarian Nordic's 2025 order book reaches €320M, FDA supports REGENXBIO's Duchenne muscular dystrophy gene therapy, Merck's subcutaneous Keytruda matches infused version, Syndax Pharmaceuticals secures FDA approval for Revuforj, Aclaris Therapeutics licenses 2 antibodies from Biosion for over $40M upfront, Sandoz to cut 10% of workforce in France, Incyte halts testing and discontinues drugs, Sage Therapeutics discontinues dalzanemdor, Johnson & Johnson and Merck announce job cuts in China, Samsung Biologics signs $668M contracts, FDA grants accelerated approval to Jazz Pharmaceuticals' Ziihera, Lexicon Pharmaceuticals cuts 60% of workforce, Halozyme withdraws €2B bid for Evotec, mpox epidemic overwhelms hospitals in Kinshasa.